Safety and Efficacy of Vanzacaftor–Tezacaftor–Deutivacaftor in Adults With Cystic Fibrosis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Respiratory Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials
Lancet Respir Med 2023 Feb 23;[EPub Ahead of Print], AZ Uluer, G MacGregor, P Azevedo, V Indihar, C Keating, MA Mall, EF McKone, BW Ramsey, SM Rowe, RC Rubenstein, JL Taylor-Cousar, E Tullis, LM Yonker, C Chu, AP Lam, N Nair, PR Sosnay, S Tian, F Van Goor, L Viswanathan, D Waltz, LT Wang, Y Xi, J Billings, A HorsleyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.